Pfizer Inc. closed 18.10% below its 52-week high of $31.54, which the company reached on July 30th.

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report). The company’s ...

PF-07976016 is under clinical development by Pfizer and currently in Phase I for Obesity ... Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and ...

in coordination with Manila – a development analysts say underscores the growing regional challenge of combating transnational crime. The Singapore Police Force told local newspaper The Straits ...

Pfizer PFE-0.49%decrease; red down pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN-0.95%decrease; red down pointing triangle for 2.50 billion ...

Such meetings between incoming and outgoing administrations are typical as a new slate of US officials gets up to speed on portfolios from counterterrorism to transnational crime and public health.

Pfizer’s CEO stated that the company revamped its commercial strategy, brought in new leadership, and exceeded market share expectations. On the cost side, Pfizer achieved $4 billion in savings ...

Get Wall Street's Hottest Chart Every Morning Pfizer’s CEO stated that the company revamped its commercial strategy, brought in new leadership, and exceeded market share expectations.